MedTrace Logo

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2021-06-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to investigate the effects of QTI571 (imatinib) on pharmacokinetics of bosentan and sildenafil at steady state when co-administered to participants with pulmonary arterial hypertension.

Conditions

Interventions

DRUG

Imatinib

Film coated tablets, oral administration

DRUG

Sildenafil

Oral Administration

DRUG

Bosentan

Oral Administration

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-20
Primary Completion
2012-10-25
Completion
2012-10-25
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Germany
  • Italy
  • Lithuania
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01392469 on ClinicalTrials.gov